As shown by the Western blot assay results, the luteolin treatment groups displayed a concentration-dependent decrease in the antiapoptotic protein Bcl2, and the proapoptotic protein bax tended to increase in both GBM cell lines (Figure 2B). This evidence concerns the gene BCL2 and glioblastoma.